Peter W Szlosarek Selected Research

Argininosuccinate Synthase (Argininosuccinate Synthetase)

11/2020	Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms.
11/2020	Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer.
1/2019	A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma.
6/2017	Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.
1/2017	Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
2/2014	Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.
12/2013	Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges.
3/2013	Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase.
6/2010	Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.
9/2009	Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter W Szlosarek Research Topics

Disease

15	Neoplasms (Cancer) 01/2022 - 09/2003
6	Malignant Mesothelioma 01/2022 - 12/2006
4	Ovarian Neoplasms (Ovarian Cancer) 06/2010 - 02/2006
3	Uveal melanoma 01/2022 - 05/2016
3	Mesothelioma 11/2020 - 03/2013
3	Melanoma (Melanoma, Malignant) 01/2017 - 06/2010
3	Carcinogenesis 07/2007 - 09/2003
2	Neoplasm Metastasis (Metastasis) 01/2022 - 07/2007
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2021 - 06/2017
2	Kidney Neoplasms (Kidney Cancer) 12/2013 - 06/2010
2	Hepatocellular Carcinoma (Hepatoma) 12/2013 - 06/2010
2	Inflammation (Inflammations) 07/2007 - 09/2003
2	Necrosis 07/2007 - 09/2003
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 11/2020
1	Disease Progression 11/2020
1	Glioma (Gliomas) 01/2019
1	Uveitis 01/2017
1	Fatigue 01/2017
1	Neutropenia 01/2017
1	Hypoxia (Hypoxemia) 03/2016
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 06/2015
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 06/2015
1	Urinary Bladder Neoplasms (Bladder Cancer) 02/2014
1	Glioblastoma (Glioblastoma Multiforme) 12/2013
1	Lymphoma (Lymphomas) 12/2013
1	Sarcoma (Soft Tissue Sarcoma) 12/2013
1	Urologic Neoplasms (Urological Cancer) 12/2013
1	Colorectal Neoplasms (Colorectal Cancer) 06/2010
1	Ovarian Epithelial Carcinoma 07/2007
1	Stomach Neoplasms (Stomach Cancer) 07/2007
1	Cytokine Release Syndrome 09/2003
1	Rheumatoid Arthritis 09/2003
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 09/2003

Drug/Important Bio-Agent (IBA)

14	Arginine (L-Arginine)FDA Link 10/2021 - 12/2006
12	Argininosuccinate Synthase (Argininosuccinate Synthetase)IBA 11/2020 - 12/2006
11	ADI PEG20IBA 01/2022 - 03/2013
7	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2006
7	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 09/2003
6	Pemetrexed (MTA)FDA Link 01/2022 - 06/2017
6	EnzymesIBA 10/2021 - 07/2007
3	CytokinesIBA 06/2010 - 02/2006
3	Proteins (Proteins, Gene)FDA Link 07/2007 - 02/2006
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2007 - 09/2003
2	pembrolizumabIBA 01/2021 - 05/2016
2	Essential Amino AcidsIBA 06/2017 - 06/2010
2	IpilimumabIBA 01/2017 - 05/2016
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 03/2016 - 07/2007
2	Urea (Carbamide)FDA LinkGeneric 02/2014 - 12/2013
2	PlatinumIBA 06/2010 - 09/2009
2	Messenger RNA (mRNA)IBA 07/2007 - 02/2006
1	tazemetostatIBA 01/2022
1	Enhancer of Zeste Homolog 2 ProteinIBA 01/2022
1	LigandsIBA 11/2020
1	Bevacizumab (Avastin)FDA Link 01/2019
1	AmmoniaIBA 06/2017
1	CitrullineIBA 06/2017
1	NivolumabIBA 01/2017
1	arginine deiminaseIBA 01/2017
1	Immune Checkpoint InhibitorsIBA 01/2017
1	Amino Acids FDA Link 06/2015
1	Pyruvic Acid (Pyruvate)IBA 11/2014
1	Folic Acid AntagonistsIBA 02/2014
1	Fumarate Hydratase (Fumarase)IBA 12/2013
1	Pharmaceutical PreparationsIBA 12/2013
1	Argininosuccinate LyaseIBA 12/2013
1	AntimetabolitesIBA 12/2013
1	Carboplatin (JM8)FDA LinkGeneric 09/2009
1	Paclitaxel (Taxol)FDA LinkGeneric 09/2009
1	Complementary DNA (cDNA)IBA 07/2007
1	RNA (Ribonucleic Acid)IBA 07/2007
1	PyrimidinesIBA 07/2007
1	Proline (L-Proline)FDA Link 07/2007
1	PolyaminesIBA 07/2007
1	Interleukin-6 (Interleukin 6)IBA 02/2006
1	Infliximab (Remicade)FDA Link 02/2006

Therapy/Procedure

7	Therapeutics 01/2022 - 09/2003
2	Drug Therapy (Chemotherapy) 01/2019 - 09/2009
1	Aftercare (After-Treatment) 01/2022
1	Immunotherapy 01/2022